12:00 AM
 | 
Oct 27, 2003
 |  BioCentury  |  Finance

BT trumps RX

BT trumps RX

Biotech
Company 3Q EPS est 3Q EPS actual Outcome Growth from 3Q02 10/24 cls Wk chg % chg Mkt cap chg ($M) 10/24 mkt cap ($M)
Affymetrix (AFFX) $0.08 $0.10 Beat by $0.02 1000% $23.69 $2.91 14% $171 $1,395
3Q03 revenues increased 5% to $76.2M, with sales increasing 13% to $71.1M. Reiterated full year sales guidance of $280M.
Amgen (AMGN) $0.51 $0.53 Beat by $0.02 56% $61.47 $(1.54) -2% $(1,985) $79,235
3Q03 sales increased 54% to $2.1B. Sales of anemia drugs Epogen and Aranesp rose 58% to $1B, and AMGN now expects to post combined 2003 sales of $3.8-$4B, up from prior guidance of $3.7-$3.9B. Most of the gains came from Aranesp, which grew 285% to $438M. Sales of neutropenia drugs Neulasta and Neupogen increased 39% to $657M. Enbrel etanercept for rheumatoid arthritis increased 116% to $342M. Reiterated its 2003 EPS guidance of $1.85-$1.95, but narrowed its annual sales range to $7.6-$7.9B from $7.5-$8B. While it raised the low end, the fact that the company lowered the high end suggested to some that growth may be waning (see Analyst Picks and Changes, B14).
Applied Bio (ABI) (B) $0.17 $0.16 Missed by $0.01 0% $22.34 $(0.42) -2% $(88) $4,656
1Q04 net revenues fell 3% to $382.7M, reflecting a 9% decrease...

Read the full 1544 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >